MDM2 and acute myeloid leukemia: The wild-type TP53 may be significantly inhibited by high levels of mouse double minute 2 homolog (MDM2) or inhibitor of apoptosis proteins (IAP); this presents an appealing targeted strategy for AML treatment [35].